Reviva Pharmaceuticals Holdings, Inc. - Common Stock (RVPH)
0.3375
-0.0205 (-5.73%)
NASDAQ · Last Trade: Jun 28th, 7:26 PM EDT
Detailed Quote
Previous Close | 0.3580 |
---|---|
Open | 0.3800 |
Bid | 0.3310 |
Ask | 0.3400 |
Day's Range | 0.3150 - 0.3857 |
52 Week Range | 0.3000 - 4.280 |
Volume | 11,480,644 |
Market Cap | 7.64M |
PE Ratio (TTM) | -0.9926 |
EPS (TTM) | -0.3 |
Dividend & Yield | N/A (N/A) |
1 Month Average Volume | 2,137,557 |
Chart
About Reviva Pharmaceuticals Holdings, Inc. - Common Stock (RVPH)
Reviva Pharmaceuticals Holdings Inc. is a biopharmaceutical company focused on developing innovative therapeutic solutions for conditions with significant unmet medical needs. The company primarily concentrates on advancing its proprietary drug candidates through clinical trials to address psychiatric, neurological, and inflammatory disorders. Reviva utilizes its expertise in pharmacology to create novel treatment options that aim to improve the lives of patients by targeting specific mechanisms of disease while minimizing side effects associated with traditional therapies. Through its research and development efforts, Reviva seeks to make meaningful contributions to the field of medicine and enhance patient outcomes. Read More
News & Press Releases
After the closing bell on Thursday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Via Chartmill · June 26, 2025
Wondering how the US markets performed one hour before the close of the markets on Thursday? Discover the movers and shakers of today's session in our comprehensive analysis.
Via Chartmill · June 26, 2025
Via Benzinga · June 26, 2025
Looking for insights into the US markets in the middle of the day on Thursday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via Chartmill · June 26, 2025
There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.
Via Chartmill · June 26, 2025
The US market session of Thursday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
Via Chartmill · June 26, 2025
Via Benzinga · June 26, 2025
Via Benzinga · June 26, 2025
Via Benzinga · June 25, 2025
After the closing bell on Wednesday, let's take a glimpse of the US markets and explore the top gainers and losers in today's after-hours session.
Via Chartmill · June 25, 2025
Via Benzinga · May 20, 2025
Stay up-to-date with the latest market trends one hour before the close of the markets on Tuesday. Explore the top gainers and losers during today's session in our detailed report.
Via Chartmill · April 1, 2025
Curious to know what's happening on the US markets in the middle of the day on Tuesday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · April 1, 2025
Investors and traders are closely monitoring the gap up and gap down stocks in today's session on Tuesday. Let's explore the market movements and identify the stocks with significant gaps.
Via Chartmill · April 1, 2025
Via Benzinga · April 1, 2025

Shoshana Shendelman Steps Down as CEO; Les Funtleyder Appointed Interim Chief Executive Officer
By Applied Therapeutics · Via GlobeNewswire · December 20, 2024

Via Benzinga · December 17, 2024

Via Benzinga · December 17, 2024

Via Benzinga · October 24, 2024

The FDA's approval of Bristol Myers Squibb's Cobenfy for schizophrenia opens doors for Reviva's brilaroxazine, a multi-receptor antipsychotic.
Via Benzinga · October 7, 2024

RVPH stock results show that Reviva Pharmaceuticals beat analyst estimates for earnings per share the second quarter of 2024.
Via InvestorPlace · August 14, 2024